studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 839A
Disclosures:
The following authors have nothing to disclose: Kazuhiro Takahashi, David
A. Bruno, Marwan Kazimi, Atsushi Yoshida, Marwan S. Abouljoud, Gabriel
Schnickel
1275
Post-Transplant Lymphoproliferative Disease is more
common in primary sclerosing cholangitis patients after
liver transplant
Ahmed Abu Shanab 1,2 , Yasser Gayed 1 , Naeem Ullah 1 , Diarmaid
D. Houlihan 1 , Aiden McCormick 1 ; 1 Liver Unit, St-Vincent University
Hospital, Dublin, Ireland; 2 Internal Medicine, Menofiya University,
Shebin Alkom, Egypt
Background: Post transplant lymphoproliferative disorder (PTLD)
is a well recognized complication of therapeutic immunosuppression
in solid organs transplant recipients. It represents a
broad spectrum of abnormalities ranging from a benign infectious
mononucleosis like illness to malignant lymphoma and
is associated with high mortality. Methods: A retrospective
study was performed by collecting data of liver transplant (LT)
patients in a single institution from December 1993 to December
2014. Data was analyzed to identify PTLD patients and
determine their demographic details, the indication for liver
transplant, presenting symptoms, immunosuppression regimens
and patient survival and PTLD outcome. Results: From a total of
705 liver transplants recipients, 20 patients (2.8%) were diagnosed
with PTLD. There were more males (n=17, 85%) than
females (n=3, 15%), with median time from LT to diagnosis of
PTLD was 83 months. The primary indication for LT of the PTLD
cohort was PSC (n=8, 40%) of overall 67 PSC post LT patients.
The rate of occurrence of PTLD in PSC was significantly higher
than the overall LT patients with p value